评估pregabalin在糖尿病外围神经病痛疼痛管理中的疗效
Tony Joseph1, Kush Modi2, Mark Genkin3
1Department of Chemistry, City University of New York-Brooklyn College, Brooklyn, NY, USA.
The Korean journal of pain
|January 15, 2026
概括
普雷加巴林有效地管理糖尿病外围神经病变 (DPN) 中的神经病痛. 它的疗效与阿米特里普提林相当,优于卡巴马西平和文拉法辛,患者耐受性好.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 糖尿病学 糖尿病学
背景情况:
- 糖尿病周围神经病变 (DPN) 是糖尿病的常见并发症,导致显著的神经病痛.
- 有效的疼痛管理对于改善DPN患者的生活质量至关重要.
研究的目的:
- 评估pregabalin对DPN疼痛的疗效,无论是单一治疗还是联合治疗.
- 为了比较Pregabalin与其他常见的DPN药物的有效性.
主要方法:
- 来自PubMed和Embase的研究的系统审查.
- 包括实验小组接受治疗的普雷加巴林,阿米特利普提林,杜洛克赛丁,卡巴马西平,文拉法辛,和小可格比配方 (XF).
主要成果:
- 普雷加巴林的疗效与阿米特里普提林相比,效果与卡巴马泽平和文拉法辛相比较强.
- 杜洛西丁在较低剂量时更有效,而普雷加巴林在较高剂量时表现出色.
- 肖克格比配方 (XF) 显示效果与普雷加巴林相似;组合疗法在普雷加巴林单一治疗上没有显著的优势.
结论:
- 普雷加巴林是治疗DPN疼痛的有效单疗法,患者可以很好地容忍它.
- 它与现有的单一疗法和组合疗法并无劣势.
- 像XF这样的草药治疗在DPN疼痛管理方面表现有前途.
相关概念视频
Peripheral Artery Disease V: Postoperative Nursing Management
378
During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
378
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K
Antiepileptic Drugs: Potassium Channel Activators
635
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
635
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
831
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
831
Analgesia and Pain Management
1.5K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.5K
Dipeptidyl Peptidase 4 Inhibitors
596
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
596


